Advanced Accelerator Applications
Manufacturing · France · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
20 Rue Diesel, Saint-Genis-Pouilly, Auve...Phone Number
+33 450993070Website
www.adacap.comRevenue
$166.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Advanced Accelerator Applications
Founded in 2002, Advanced Accelerator Applications is a pharmaceutical group specialized in the field of nuclear medicine. The group operates in all three segments of nuclear medicine to diagnose and treat serious conditions in the fields of oncology, neurology, cardiology, infectious and inflammatory diseases. The company is headquartered in Saint-Genis-Pouilly, France.Explore more
Advanced Accelerator Applications Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Advanced Accelerator Applications your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Advanced Accelerator Applications
Website visits: Recent activity has been detected on your website
Click to see if Advanced Accelerator Applications had a recent Job posting/layoffs
Earning: See what the market has to say on Advanced Accelerator Applications recently announced quarterly report
Check out if Advanced Accelerator Applications is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Advanced Accelerator Applications has recently received funding, and reach out quickly before it becomes old news!
Advanced Accelerator Applications, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Advanced Accelerator Applications launches new products
Funding: Get notified immidiatlly once Advanced Accelerator Applications has new funding data
Recommended Actions
Reach out to Masked Content who joined Advanced Accelerator Applications as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Advanced Accelerator Applications is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Advanced Accelerator Applications is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Advanced Accelerator Applications.
Advanced Accelerator Applications financials insights
Gather financial insights about Advanced Accelerator Applications, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Unspecified
$56.4M
2015
Stock Offering
$75M
Advanced Accelerator Applications Tech Stack
A closer look at the technologies used by Advanced Accelerator Applications
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Facilities Relocation / Expansion
Advanced Accelerator Applications is planning to move offices in October 2026. The move will impact approximately 70 employees at the existing office located at 57 E Willow St, Millburn, NJ.
Facilities Relocation/Expansion
Open Position
Open Position
Open Position
Advanced Accelerator Applications News & Media
Gastroenteropancreatic Neuroendocrine Tumors Market to Showcase a Significant Growth by 2032, Evaluates DelveInsight | Key Players - Eli Lilly and Company, Phanes Therapeutics, Camurus AB, Advanced Accelerator Applications, PharmaMar
The global GEP-NET therapeutics market is further expected to increase by the major drivers such as rising incident population, technological advancements, increased funding for new drug development and clinical trials, increasing awareness among common people, increasing research...Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer
Ad hoc announcement pursuant to Art. 53 LR FDA also approved complementary diagnostic imaging agent, Locametz®, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions2 Metastatic prostate cancer has a 5-year survival rate of less than 30%3; mCRPC patients who progress on multiple lines of therapy have limited treatment options FDA approval was based on pivotal Phase III VISION trial, where patients with pre-treated PSMA-positive mCRPC who received Pluvicto plus standCancer Targeted Technology Receives Milestone Payment for Development of Diagnostic PET Imaging Agent for Prostate Cancer
SEATTLE--(BUSINESS WIRE)--Cancer Targeted Technology receives milestone paymentAdvanced Accelerator Applications to Build Targeted Radioligand Therapy Production Facility in Indianapolis
SAINT-GENIS-POUILLY, France, June 30, 2020 /PRNewswire/ -- Advanced Accelerator Applications S.A. (AAA), a Novartis company, today announced it has executed a sales and purchase agreement for land on which a 50,000 square foot targeted Radioligand Therapy (RLT) manufacturing plant will be...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Advanced Accelerator Applications
Sign Up For FreeTo access detailed company insights
Founded in 2002, Advanced Accelerator Applications is a pharmaceutical group specialized in the field of nuclear medicine. The group operates in all three segments of nuclear medicine to diagnose and treat serious conditions in the fields of oncology, neurology, cardiology, infectious and inflammatory diseases. The company is headquartered in Saint... Read More
